

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

500 doses, Bottle of 150 ml  
10 x 500 doses, 10 Bottles of 150 ml  
1000 doses, Bottle of 300 ml  
10 x 1000 doses, 10 Bottles of 300 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

GALLIMUNE 302 ND+IB+EDS emulsion for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 0.3 ml dose contains:

Inactivated Newcastle disease virus, Ulster 2C strain..... $\geq 50$  PD<sub>50</sub>  
Inactivated infectious bronchitis virus, Mass41 strain..... $\geq 18$  HI.U  
Inactivated egg drop syndrome virus (EDS76), V127 strain..... $\geq 180$  HI.U

**3. PACKAGE SIZE**

0.3 ml/d  
500 doses (150 ml)  
10 x 500 doses (10 x 150 ml)  
1 000 doses (300 ml)  
10 x 1 000 doses (10 x 300 ml)

**4. TARGET SPECIES**

Chickens (breeder and layer pullets).

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

For intramuscular use.  
Shake well before use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: zero days.

**8. EXPIRY DATE**

Exp.: {dd/mm/yyyy}  
Once opened use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.  
Protect from light.  
Do not freeze.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Boehringer Ingelheim Vetmedica GmbH

**14. MARKETING AUTHORISATION NUMBER**

Vm 61700/3008

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

500 doses, 150 ml  
1000 doses, 300 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

GALLIMUNE 302 ND+IB+EDS emulsion for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Per dose:

Inactivated:

- Newcastle disease virus, Ulster 2C strain ..... $\geq 50$  PD<sub>50</sub>,
- infectious bronchitis virus, Mass41 strain ..... $\geq 18$  HI.U,
- egg drop syndrome virus (EDS76), V127 strain ..... $\geq 180$  HI.U,

0.3 ml/d

500 doses

1 000 doses

**3. TARGET SPECIES**

Chickens (breeder and layer pullets)

**4. ROUTES OF ADMINISTRATION**

For intramuscular use.

Shake well before use.

Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal period: zero days.

**6. EXPIRY DATE**

Exp. {dd/mm/yyyy}

Once opened use immediately.

**7. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Protect from light.

Do not freeze.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Boehringer Ingelheim Vetmedica GmbH

**9. BATCH NUMBER**

Lot {number}

**B. PACKAGE LEAFLET**

## **PACKAGE LEAFLET**

### **1. Name of the veterinary medicinal product**

GALLIMUNE 302 ND+IB+EDS emulsion for injection

### **2. Composition**

Each 0.3 ml dose contains:

Inactivated Newcastle disease virus, Ulster 2C strain.....	≥ 50 PD <sub>50</sub> <sup>1</sup>
Inactivated infectious bronchitis virus, Mass41 strain.....	≥ 18 HI.U
Inactivated egg drop syndrome virus (EDS76), V127 strain.....	≥ 180 HI.U
Thiomersal .....	30 µg
Formaldehyde .....	≤ 43.2 µg
Paraffin oil (as adjuvant).....	170 to 186 mg

The concentrations are expressed by the antibody titre obtained during the potency test.

One unit (U) corresponding to an antibody titre of 1.

HI: haemagglutination inhibiting

<sup>1</sup> Minimum protective dose according to monograph 0870 of Ph. Eur.

Whitish homogeneous emulsion.

### **3. Target species**

Chickens (breeder and layer pullets).

### **4. Indications for use**

Booster immunisation of breeder and layer pullets after vaccination with live vaccines against:

- Newcastle disease virus
- infectious bronchitis virus

Active immunisation of breeder and layer pullets in order to reduce egg drop linked to infection with egg drop syndrome virus (EDS76) without priming.

Onset of immunity: 4 weeks after vaccination.

Duration of immunity: one laying period.

### **5. Contraindications**

None.

### **6. Special warning(s)**

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.

If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Laying birds:

Do not use in birds in lay and within 2 weeks before the start of the laying period.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

In addition to the adverse events mentioned in paragraph "Adverse events", transitory apathy and slight oedema at injection site may occur after the administration of a double dose of vaccine.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

## **7. Adverse events**

Chickens:

### **Very common (> 1 animal / 10 animals treated):**

Abnormal histology<sup>1</sup>

<sup>1</sup> In clinical studies, lesions at the injection site linked to the oily adjuvant were observed histologically three weeks after injections in 87 % of cases, e.g. small quantities of oily residues and occasional aseptic micro-abscesses. No palpable reactions were observed.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

## **8. Dosage for each species, routes and method of administration**

Administer one dose (0.3 ml) by intramuscular route from the age of 18 weeks and at least 4 weeks after the priming with live vaccines against Newcastle disease (strain Hitchner B1 or VG/GA-AVINEW) and infectious bronchitis (strain Mass H120).

## **9. Advice on correct administration**

- Shake well before use.
- Apply usual aseptic procedures.
- Do not use syringes with natural rubber or butyl elastomer pistons.
- Equipment including needles and syringes must be sterile before use.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**

Keep out of the reach and sight of children.

Store and transport refrigerated (2 °C – 8 °C).

Protect from light.

Do not freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after “Exp.”.

Shelf life after first opening the immediate packaging: use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **14. Marketing authorisation numbers and pack sizes**

Vm 61700/3008

Pack sizes:

- 150-ml (500-dose) bottle.
- 150-ml (500-dose) bottle, box of 10 bottles.
- 300-ml (1 000-dose) bottle.
- 300-ml (1 000-dose) bottle, box of 10 bottles.

Not all pack sizes may be marketed.

**15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

**16. Contact details**

Marketing authorisation holder:  
Boehringer Ingelheim Vetmedica GmbH  
Binger Strasse 173  
55216 Ingelheim am Rhein  
Germany

Manufacturer responsible for the batch release:  
Boehringer Ingelheim Animal Health France SCS  
Laboratoire Porte des Alpes  
Rue de l'Aviation  
69800 Saint-Priest  
France

Local representatives and contact details to report suspected adverse reactions:  
To be completed nationally.

**17. Other information**

Inactivated vaccine in oily adjuvant against Newcastle disease, infectious bronchitis and egg drop syndrome (EDS76).

*Gavin Hall*  
Approved: 02 December 2025